Abstract
Aim:
The possibility that angiotensin-converting enzyme inhibitors can protect hypertensive kidneys independently of any blood pressure (BP) decrease remains a matter of controversy. The present study investigates this theory in Lyon genetically-hypertensive (LH) rats.
Methods:
Male rats were used in the present study and were untreated (controls) or orally received 0.4, 0.1, 0.04, and 0.01 mg·kg−1·d−1 doses of perindopril from 3 to 17 weeks of age. At 16 and 23 weeks of age (ie during treatment and 6 weeks after its cessation), systolic BP (SBP) was measured by plethysmography, and urine was collected to measure the urinary protein (Uprot) and N-acetyl-seryl-aspartyl-lysyl-proline-to-creatinine (Cr) concentrations. The kidneys were dissected for a semiquantitative histological analysis.
Results:
SBP was significantly lowered (−18%±2% and −11%±1% from controls at 16 and 23 weeks, respectively) with a 0.4 mg·kg−1·d−1 dose of perindopril. Lower doses did not affect SBP. Uprot/Cr decreased, and Ac-SDKP/Cr increased with all the doses of perindopril used. Uprot/Cr remained lower at 23 weeks in the rats treated with 0.1 mg·kg−1·d−1 and smaller doses. The ratio of Uprot/Cr was closely (r =0.6) related to the histological lesions score.
Conclusion:
In LH rats, low doses of perindopril induce renoprotection which is independent of SBP decrease and persists after withdrawal of treatment.
Similar content being viewed by others
Article PDF
References
Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36: 646–61.
Keane WF, Brenner BM, De Zeeuw D, Grunfeld JP, McGill J, Mitch WE, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL STUDY. Kidney Int 2003; 63: 1499–507.
Remuzzi A, Imberti O, Puntorieri S, Malanchini B, Macconi D, Magrini L, et al. Dissociation between antiproteinuric and anti-hypertensive effect of angiotensin converting enzyme inhibitors in rats. Am J Physiol 1994; 267: F1034–F1044.
Opie L . Renoprotection by angiotensin-receptor blockers and ACE inhibitors in hypertension. The Lancet 2001; 358: 1829–31.
Viberti G, Wheeldon NM . Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672–8.
Isogai S, Kameyama M, Iso K, Yoshino G . Protective effects of a small dose of captopril on the reduction of glomerular basement membrane anionic sites in spontaneously hypertensive rats with strep-tozocin-induced diabetes. J Diabetes complications 1998; 12: 170–5.
Linz W, Becker R, Scholkens B, Wiemer G, Keil M, Langer KH . Nephroprotection by long-term ACE inhibition with ramipril in spontaneously hypertensive stroke prone rats. Kidney Int 1998; 54: 2037–44.
Keilani T, Danesh F, Schlueter W, Molteni A, Batlle D . A subdepres-sor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium. Am J Kidney Dis 1999; 33: 450–7.
Suyama K, Muso E, Yashiro M, Sasayama S . Significant suppressive effect of low-dose temocapril, an ACE inhibitor with biliary excretion, on FGS lesions in hypertensive rats. Nephron 2000; 86: 491–8.
Toto RD, Adams-Huet B, Fenvers AZ, Mitchell HC, Mulcahy W, Smith RD . Effect of ramipril on blood pressure and protein excretion rate in normotensive nondiabetic patients with proteinuria. Am J Kidney Dis 1996; 28: 832–42.
Rostoker G, Ben-Maadi A, Remy P, Lang P, Lagrue G, Weil B . Low-dose angiotensin converting enzyme inhibitor captopril to reduce proteinuria in adult idiopathic membranous nephropathy: A prospective study of long-term treatment. Nephrol Dial Transplant 1995; 10: 25–9.
Bidani A, Griffin K, Bakris G, Picken M . Lack of evidence of BP-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int 2000; 57: 1651–61.
Griffin K, Abu-Amarah I, Picken M, Bidani A . Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent. Hypertension 2003; 41: 201–6.
Lasaridis AN, Sarafidis PA . Diabetic nephropathy and antihyperten-sive treatment: What are the lessons from clinical trials? Am J Hy-pertens 2003; 16: 689–97.
Vaur L, Gueret P, Lievre M, Chabaud S, Passa P . DIABHYCAR Study Group (type 2 DIABetes, Hypertension, CARdiovascular Events and Ramipril) study. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: Observation from the DIABHYCAR (type 2 DIABetes, Hypertension, Cardiovascular events and ramipril) study. Diabetes Care 2003; 26: 855–60.
Vincent M, Sassard J . Lyon strains. In: Swales JD, editor. Textbook of hypertension. Oxford: Blackwell Scientific; 1994. p 455–7.
Lantelme P, Lo M, Luttenauer L, Sassard J . Pivotal role of the renin-angiotensin system in Lyon hypertensive rats. Am J Physiol Regul IntegrComp Physiol 1997; 273: R1793–R1799.
Bertram D, Blanc-Brunat N, Sassard J, Lo M . Differential evolution of blood pressure and renal lesions after RAS blockade in Lyon hypertensive rats. Am J Physiol Regul Integr Comp 2002; 283: R104–15.
Ezan E, Carde P, Le Kerneau J, Ardouint T, Thomas F, Isnard F, et al. Pharmacokinetics in healthy volunteers and patients of NAc-SDKP (seraspenide), a negative regulator of hematopoiesis. Drug Metab Dispos 1994; 22: 843–8.
Blanc-Brunat N, Vincent M, Sassard J . Evolution des lésions rénales précoces chez trois souchess de rats génétiquement hypertendus, normotendus et normotendus bas. Arterial Wall 1980; 6: 145–56 (in French).
Kurtz TW . False claims of blood pressure-independent protection by blockade of the renin angiotensin aldosterone system. Hypertension 2003; 41: 193–6.
Pires S, Julien C, Chapuis B, Sassard J, Barrès C . Spontaneous renal blood flow autoregulation curves in conscious sinoaortic denervated rats. Am J Physiol Renal Physiol 2002; 282: F515–8.
Garret MR, Dene H, Rapp JP . Time-course genetic analysis of albuminuria in Dahl salt-sensitive rats on low-salt diet. J Am Soc Nephrol 2003; 14: 1175–87.
D'Amico G, Bazzi C . Pathophysiology of proteinuria. Kidney Int 2003; 63: 809–25.
Florin M, Lo M, Liu KL, Sassard J . Salt sensitivity in genetically hypertensive rats of the Lyon strains. Kidney Int 2001; 59: 1865–72.
Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, Kurokawa K, et al. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 2003; 42: 31–8.
Franco M, Tapia E, Santamaria J, Zafra I, García-Torres R, Gordon KL, et al. Renal cortical vasoconstriction contributes to development of salt sensitive hypertension after angiotensin II exposure. J Am Soc Nephrol 2001; 12: 2263–71.
Muller DN, Shagdarsuren E, Park JK, Dechend R, Mervaala E, Ham-pich F, et al. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol 2002; 161: 1679–93.
Del Prete D, Gambaro G, Lupo A, Anglani F, Brezzi B, Magistroni R, et al. Precocious activation of genes of the renin-angiotensin system and the fibrogenic cascade in IgA glomerulonephritis. Kidney Int 2003; 64: 149–59.
Ruiz-Ortega M, Ruperez M, Lorenzo O, Anglani F, Brezzi B, Magistroni R, et al. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int 2002; Suppl 82: 12–22.
Kuno A, Yamada T, Masuda K, Ogawa K, Sogawa M, Nakamura S, et al. Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. Gastro-enterology 2003; 124: 1010–9.
Wang D, Yang XP, Rhaleb NE, Beierwaltes WH, Carretero OA . Renoprotective effect of Ac-SDKP in Dahl salt-sensitive rats. Hypertension 2003; 42: 418 (abst).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Egan, E., Dijoud, F., Gilibert, S. et al. Renoprotection persists after cessation of treatment with very low doses of perindopril in Lyon hypertensive rats. Acta Pharmacol Sin 29, 1296–1300 (2008). https://doi.org/10.1111/j.1745-7254.2008.00862.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2008.00862.x